21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Dynamic tuneable G protein-coupled receptor monomer-dimer populations

      research-article

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          G protein-coupled receptors (GPCRs) are the largest class of membrane receptors, playing a key role in the regulation of processes as varied as neurotransmission and immune response. Evidence for GPCR oligomerisation has been accumulating that challenges the idea that GPCRs function solely as monomeric receptors; however, GPCR oligomerisation remains controversial primarily due to the difficulties in comparing evidence from very different types of structural and dynamic data. Using a combination of single-molecule and ensemble FRET, double electron–electron resonance spectroscopy, and simulations, we show that dimerisation of the GPCR neurotensin receptor 1 is regulated by receptor density and is dynamically tuneable over the physiological range. We propose a “rolling dimer” interface model in which multiple dimer conformations co-exist and interconvert. These findings unite previous seemingly conflicting observations, provide a compelling mechanism for regulating receptor signalling, and act as a guide for future physiological studies.

          Abstract

          Evidence suggests oligomerisation of G protein-coupled receptors in membranes, but this is controversial. Here, authors use single-molecule and ensemble FRET, and spectroscopy to show that the neurotensin receptor 1 forms multiple dimer conformations that interconvert - “rolling” interfaces.

          Related collections

          Most cited references58

          • Record: found
          • Abstract: found
          • Article: not found

          Bayesian estimation supersedes the t test.

          Bayesian estimation for 2 groups provides complete distributions of credible values for the effect size, group means and their difference, standard deviations and their difference, and the normality of the data. The method handles outliers. The decision rule can accept the null value (unlike traditional t tests) when certainty in the estimate is high (unlike Bayesian model comparison using Bayes factors). The method also yields precise estimates of statistical power for various research goals. The software and programs are free and run on Macintosh, Windows, and Linux platforms. PsycINFO Database Record (c) 2013 APA, all rights reserved.
            • Record: found
            • Abstract: found
            • Article: not found

            Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists.

            Chemokine receptors are critical regulators of cell migration in the context of immune surveillance, inflammation, and development. The G protein-coupled chemokine receptor CXCR4 is specifically implicated in cancer metastasis and HIV-1 infection. Here we report five independent crystal structures of CXCR4 bound to an antagonist small molecule IT1t and a cyclic peptide CVX15 at 2.5 to 3.2 angstrom resolution. All structures reveal a consistent homodimer with an interface including helices V and VI that may be involved in regulating signaling. The location and shape of the ligand-binding sites differ from other G protein-coupled receptors and are closer to the extracellular surface. These structures provide new clues about the interactions between CXCR4 and its natural ligand CXCL12, and with the HIV-1 glycoprotein gp120.
              • Record: found
              • Abstract: found
              • Article: not found

              Crystal structure of the μ-opioid receptor bound to a morphinan antagonist

              Summary Opium is one of the world’s oldest drugs, and its derivatives morphine and codeine are among the most used clinical drugs to relieve severe pain. These prototypical opioids produce analgesia as well as many of their undesirable side effects (sedation, apnea and dependence) by binding to and activating the G-protein-coupled μ-opioid receptor (μOR) in the central nervous system. Here we describe the 2.8 Å crystal structure of the μOR in complex with an irreversible morphinan antagonist. Compared to the buried binding pocket observed in most GPCRs published to date, the morphinan ligand binds deeply within a large solvent-exposed pocket. Of particular interest, the μOR crystallizes as a two-fold symmetric dimer through a four-helix bundle motif formed by transmembrane segments 5 and 6. These high-resolution insights into opioid receptor structure will enable the application of structure-based approaches to develop better drugs for the management of pain and addiction.

                Author and article information

                Contributors
                mark.wallace@kcl.ac.uk
                anthony.watts@bioch.ox.ac.uk
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                27 April 2018
                27 April 2018
                2018
                : 9
                : 1710
                Affiliations
                [1 ]ISNI 0000 0004 1936 8948, GRID grid.4991.5, Biomembrane Structure Unit, Department of Biochemistry, , University of Oxford, ; South Parks Road, Oxford, OX1 3QU UK
                [2 ]ISNI 0000 0004 1936 8948, GRID grid.4991.5, Department of Chemistry, , University of Oxford, ; South Parks Road, Oxford, OX1 3QU UK
                [3 ]ISNI 0000 0001 0807 5670, GRID grid.5600.3, School of Pharmacy and Pharmaceutical Sciences, College of Biomedical and Life Sciences, , Cardiff University, King Edward VII Avenue, ; Cardiff, CF10 3NB UK
                [4 ]ISNI 0000 0004 1754 9227, GRID grid.12380.38, Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute for Molecules, Medicines and Systems (AIMMS), , Vrije Universiteit Amsterdam, ; De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands
                [5 ]ISNI 0000 0001 1018 9466, GRID grid.419494.5, Present Address: Max Planck Institute for Biophysics, ; Max-von-Laue-Straße 3, 60438 Frankfurt am Main, Germany
                [6 ]ISNI 0000 0004 0376 4727, GRID grid.7273.1, Present Address: School of Life and Health Sciences, , Aston University, Aston Triangle, ; Birmingham, B4 7ET UK
                [7 ]ISNI 0000 0001 1092 7967, GRID grid.8273.e, Present Address: School of Pharmacy, , University of East Anglia, Norwich Research Park, ; Norwich, NR4 7TJ UK
                [8 ]ISNI 0000 0001 2322 6764, GRID grid.13097.3c, Present Address: Department of Chemistry, , King’s College London, Britannia House, ; 7 Trinity Street, London, SE1 1DB UK
                Author information
                http://orcid.org/0000-0002-1226-2150
                http://orcid.org/0000-0002-5692-8313
                Article
                3727
                10.1038/s41467-018-03727-6
                5923235
                29703992
                f8856939-66cc-4cea-b19e-40655ab66aa5
                © The Author(s) 2018

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 5 April 2017
                : 6 March 2018
                Categories
                Article
                Custom metadata
                © The Author(s) 2018

                Uncategorized
                Uncategorized

                Comments

                Comment on this article

                Related Documents Log